{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:04:31Z","timestamp":1793232271351,"version":"4.5.0"},"reference-count":300,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["NCT04077437"],"award-info":[{"award-number":["NCT04077437"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FG 18"],"award-info":[{"award-number":["FG 18"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["DACH I3875 -B26"],"award-info":[{"award-number":["DACH I3875 -B26"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.neuropharm.2023.109418","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T11:10:59Z","timestamp":1673003459000},"page":"109418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-3370","authenticated-orcid":false,"given":"Nicolas","family":"Singewald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone B.","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109418_bib1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","article-title":"Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial","volume":"47","author":"Abdallah","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.euroneuro.2019.10.011","article-title":"Nutritional psychiatry: towards improving mental health by what you eat","volume":"29","author":"Adan","year":"2019","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109418_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272732","article-title":"The effectiveness of psychological interventions for reducing PTSD and psychological distress in first responders: a systematic review and meta-analysis","volume":"17","author":"Alshahrani","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109418_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuropharm.2017.06.017","article-title":"Synaptic functions of endocannabinoid signaling in health and disease","volume":"124","author":"Araque","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1089\/jwh.2019.8247","article-title":"Sex as a biological variable: a 5-year progress report and call to action","volume":"29","author":"Arnegard","year":"2020","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.neuropharm.2023.109418_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101439","article-title":"Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: a retrospective case series","volume":"48","author":"Artin","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.neuropharm.2023.109418_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13543784.2022.2035358","article-title":"Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine","volume":"31","author":"Averill","year":"2022","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2023.109418_bib8","series-title":"Anxiety Disorders: Rethinking and Understanding Recent Discoveries, Advances in Experimental Medicine and Biology","first-page":"367","article-title":"Role of benzodiazepines in anxiety disorders","author":"Balon","year":"2020"},{"key":"10.1016\/j.neuropharm.2023.109418_bib9","first-page":"1","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders \u2013 version 3. Part I: anxiety disorders","author":"Bandelow","year":"2022","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib10","first-page":"1","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders \u2013 version 3. Part II: OCD and PTSD","author":"Bandelow","year":"2022","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41583-021-00513-0","article-title":"Sex differences in anxiety and depression: circuits and mechanisms","volume":"22","author":"Bangasser","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109298","article-title":"Sex differences in fear responses: neural circuits","volume":"222","author":"Bauer","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bionps.2022.100052","article-title":"Neurocircuitry of treatment in anxiety disorders","volume":"6","author":"Baumel","year":"2022","journal-title":"Biomarkers Neuropsychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1017\/S0033291713003243","article-title":"The global burden of anxiety disorders in 2010","volume":"44","author":"Baxter","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/milmed\/usz260","article-title":"Novel pharmacological targets for combat PTSD\u2014metabolism, inflammation, the gut microbiome, and mitochondrial dysfunction","volume":"185","author":"Bersani","year":"2020","journal-title":"Mil. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib17","author":"Bonomi"},{"key":"10.1016\/j.neuropharm.2023.109418_bib18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.conb.2018.02.011","article-title":"Sex differences in the regulation of social and anxiety-related behaviors: insights from vasopressin and oxytocin brain systems","volume":"49","author":"Bredewold","year":"2018","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1017\/S0033291720000410","article-title":"A mechanistic model for individualised treatment of anxiety disorders based on predictive neural biomarkers","volume":"50","author":"Brehl","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib20","first-page":"427","article-title":"Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial","volume":"175","author":"Brunet","year":"2018","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.neuropharm.2023.109418_bib21","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1111\/bph.12779","article-title":"Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders","volume":"171","author":"Bukalo","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173660","article-title":"D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: a meta-analysis","volume":"12","author":"B\u00fcrkner","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109418_bib23","first-page":"472","article-title":"Targeting the microbiota-gut-brain Axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice","volume":"82","author":"Burokas","year":"2017","journal-title":"Biol. Psycjiatr. Stress: Mech. Gut. Brain"},{"key":"10.1016\/j.neuropharm.2023.109418_bib24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001852","article-title":"Treatment-resistant anxiety disorders","volume":"11","author":"Bystritsky","year":"2006","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/JEP.S261403","article-title":"Experimental drugs for panic disorder: an updated systematic review","volume":"13","author":"Caldirola","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/schbul\/sbs117","article-title":"Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis","volume":"39","author":"Carhart-Harris","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2023.109418_bib27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/da.22728","article-title":"Cognitive behavioral therapy for anxiety and related disorders: a meta-analysis of randomized placebo-controlled trials","volume":"35","author":"Carpenter","year":"2018","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib28","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3389\/fnins.2020.616298","article-title":"Looking for novelty in an \u201cold\u201d receptor: recent advances toward our understanding of GABAARs and their implications in receptor pharmacology","volume":"14","author":"Castellano","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","article-title":"Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning","volume":"228","author":"Catlow","year":"2013","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108035","article-title":"GABAkines \u2013 advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors","volume":"234","author":"Cerne","year":"2022","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109418_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580378","article-title":"Neuropeptide Y is an immunomodulatory factor: direct and indirect","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41401-018-0185-5","article-title":"Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety","volume":"40","author":"Chen","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2023.109418_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11920-020-1140-y","article-title":"Gender- and sex-based contributors to sex differences in PTSD","volume":"22","author":"Christiansen","year":"2020","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2023.109418_bib34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2023.109418_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-00975-3","article-title":"l -DOPA and consolidation of fear extinction learning among women with posttraumatic stress disorder","volume":"10","author":"Cisler","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/0269881117748903","article-title":"The effect of ketamine on the consolidation and extinction of contextual fear memory","volume":"32","author":"Clifton","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027925","article-title":"Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder","volume":"9","author":"Costello","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.neuropharm.2023.109418_bib38","article-title":"Anxiety disorders","volume":"3","author":"Craske","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.neuropharm.2023.109418_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/2470547020981670","article-title":"Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial","author":"Dadabayev","year":"2020","journal-title":"Chronic Stress"},{"key":"10.1016\/j.neuropharm.2023.109418_bib40","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpsychires.2020.07.046","article-title":"Pharmacological treatments for adults with post-traumatic stress disorder: a network meta-analysis of comparative efficacy and acceptability","volume":"130","author":"de Moraes Costa","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00213-018-5116-0","article-title":"Glucocorticoid-induced enhancement of extinction-from animal models to clinical trials","volume":"236","author":"de Quervain","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109418_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics","volume":"12","author":"de Vos","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/da.22737","article-title":"Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: an individual patient data meta-analysis","volume":"35","author":"de Vries","year":"2018","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.biopsych.2019.07.009","article-title":"Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies","volume":"86","author":"DePierro","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib46","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.xphs.2021.08.012","article-title":"Improved bioavailability with dry powder cannabidiol inhalation: a phase 1 clinical study","volume":"110","author":"Devinsky","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib47","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","article-title":"Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines","volume":"25","author":"Dias","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41398-022-02066-x","article-title":"Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer","volume":"12","author":"Difede","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gtc.2016.09.007","article-title":"The microbiome-gut-brain Axis in health and disease","volume":"46","author":"Dinan","year":"2017","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"10.1016\/j.neuropharm.2023.109418_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12967-017-1237-1","article-title":"Xenon in the treatment of panic disorder: an open label study","volume":"15","author":"Dobrovolsky","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib51","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/d41586-022-02874-7","article-title":"Your brain on psychedelics","volume":"609","author":"Drew","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109418_bib52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/da.22353","article-title":"Updated meta-analysis of classical fear conditioning in the anxiety disorders","volume":"32","author":"Duits","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib53","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.neuron.2022.03.001","article-title":"Laboratory models of post-traumatic stress disorder: the elusive bridge to translation","volume":"110","author":"Dunsmoor","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109418_bib54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/YIC.0000000000000356","article-title":"Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: exploratory study","volume":"36","author":"Elnazer","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib55","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65280","article-title":"L-DOPA modulates activity in the vmPFC, nucleus accumbens, and VTA during threat extinction learning in humans","volume":"10","author":"Esser","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2023.109418_bib57","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1176\/appi.ajp.2017.17070818","article-title":"The danger of LeDoux and pine's two-system framework for fear","volume":"174","author":"Fanselow","year":"2017","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib58","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2174\/1568026616666160204121039","article-title":"A systematic review of plant-derived natural compounds for anxiety disorders","volume":"16","author":"Farzaei","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109418_bib59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.apha.2020.05.004","article-title":"The emergence of ketamine as a novel treatment for posttraumatic stress disorder","volume":"89","author":"Feder","year":"2020","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib62","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/10715762.2018.1475733","article-title":"The role of oxidative stress in anxiety disorder: cause or consequence?","volume":"52","author":"Fedoce","year":"2018","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","article-title":"MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?","volume":"84","author":"Feduccia","year":"2018","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib64","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1570159X15666171123201142","article-title":"Imaging the role of inflammation in mood and anxiety-related disorders","volume":"16","author":"Felger","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104724","article-title":"Don't be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: a systematic review","volume":"139","author":"Felsch","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib66","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41583-018-0039-7","article-title":"Brain circuit dysfunction in post-traumatic stress disorder: from mouse to man","volume":"19","author":"Fenster","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.coph.2018.02.004","article-title":"Metabotropic glutamate receptors as targets for novel anxiolytics","volume":"38","author":"Ferraguti","year":"2018","journal-title":"Curr. Opin. Pharmacol. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib68","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/bph.13001","article-title":"AQW051, a novel, potent and selective \u03b17 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation","volume":"172","author":"Feuerbach","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib69","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.tins.2019.07.002","article-title":"Anxiety and brain mitochondria: a bidirectional crosstalk","volume":"42","author":"Filiou","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib70","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41380-017-0006-0","article-title":"Lost in translation: how to upgrade fear memory research","volume":"23","author":"Flores","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-clinpsy-021815-093533","article-title":"The efficacy of exposure therapy for anxiety-related disorders and its underlying mechanisms: the case of OCD and PTSD","volume":"12","author":"Foa","year":"2016","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.neuropharm.2018.05.009","article-title":"Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: implications for the pathophysiology and treatment of anxiety disorders","volume":"137","author":"Fortress","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-010-1873-0","article-title":"Measuring anxiety- and locomotion-related behaviours in mice: a new way of using old tests","volume":"211","author":"Fraser","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109418_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269772","article-title":"An umbrella review on the use of antipsychotics in anxiety disorders: a registered report protocol","volume":"17","author":"Garakani","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109418_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.595584","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109211","article-title":"Pharmacological strategies for post-traumatic stress disorder (PTSD): from animal to clinical studies","volume":"218","author":"Gasparyan","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib78","article-title":"Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system","author":"Gautam","year":"2022","journal-title":"Mol. Divers."},{"key":"10.1016\/j.neuropharm.2023.109418_bib79","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI130808","article-title":"GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions","volume":"130","author":"Gerhard","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2023.109418_bib80","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-019-05301-4","article-title":"L-DOPA improves extinction memory retrieval after successful fear extinction","author":"Gerlicher","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib81","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaac.2018.03.017","article-title":"Results from the child\/adolescent anxiety multimodal extended long-term study (CAMELS): primary anxiety outcomes","volume":"57","author":"Ginsburg","year":"2018","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2016.12.026","article-title":"Ketamine accelerates fear extinction via mTORC1 signaling","volume":"100","author":"Girgenti","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2023.109418_bib83","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jnr.25017","article-title":"Hallucinogenic drugs and their potential for treating fear-related disorders: through the lens of fear extinction","volume":"100","author":"Glavonic","year":"2022","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib84","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0269881117705089","article-title":"Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders","volume":"31","author":"Glue","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib85","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","article-title":"Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study","volume":"34","author":"Glue","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib86","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","article-title":"Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study","volume":"34","author":"Glue","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib87","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0269881118762073","article-title":"Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders","volume":"32","author":"Glue","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-022-02090-x","article-title":"Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety","volume":"12","author":"Gorka","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib89","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40290-020-00343-y","article-title":"The NIMH \u2018fast-fail trials\u2019 (FAST) initiative: rationale, promise, and progress","volume":"34","author":"Grabb","year":"2020","journal-title":"Pharm. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib90","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50 years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109418_bib91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110116","article-title":"The endocannabinoid system in the amygdala and modulation of fear","volume":"105","author":"Gunduz-Cinar","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib93","article-title":"Selective sub-nucleus effects of intra-amygdala oxytocin on fear extinction","volume":"112798","author":"Gunduz-Cinar","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib94","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/npp.2015.318","article-title":"Fluoxetine facilitates fear extinction through amygdala endocannabinoids","volume":"41","author":"Gunduz-Cinar","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib95","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tips.2013.08.008","article-title":"Amygdala FAAH and anandamide: mediating protection and recovery from stress","volume":"34","author":"Gunduz-Cinar","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib96","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/mp.2012.72","article-title":"Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity","volume":"18","author":"Gunduz-Cinar","year":"2013","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib97","article-title":"Combination therapy with neuropeptides for the treatment of anxiety disorder","volume":"102127","author":"Gupta","year":"2021","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2023.109418_bib98","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","article-title":"Cost of disorders of the brain in Europe 2010","volume":"21","author":"Gustavsson","year":"2011","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109418_bib99","doi-asserted-by":"crossref","first-page":"E2428","DOI":"10.1073\/pnas.1303061110","article-title":"Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear","volume":"110","author":"Haaker","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109418_bib100","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/nn.4111","article-title":"Finding translation in stress research","volume":"18","author":"Hariri","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib101","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brat.2014.02.004","article-title":"Benzodiazepine treatment can impair or spare extinction, depending on when it is given","volume":"56","author":"Hart","year":"2014","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.neuropharm.2023.109418_bib102","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/mpr.1560","article-title":"Optimizing exposure-based CBT for anxiety disorders via enhanced extinction: design and methods of a multicentre randomized clinical trial","volume":"26","author":"Heinig","year":"2017","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib105","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.euroneuro.2022.07.012","article-title":"Anxiety genetics: updates on genome-wide association, methylome-wide association, and childhood risk","volume":"63","author":"Hettema","year":"2022","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109418_bib106","first-page":"228","article-title":"Healthcare costs and quality of life associated with the long-term outcome of anxiety disorders","volume":"34","author":"Higgins","year":"2021","journal-title":"Hist. Philos. Logic"},{"key":"10.1016\/j.neuropharm.2023.109418_bib107","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0000000000000858","article-title":"Placebo effects across self-report, clinician rating, and objective performance tasks among women with post-traumatic stress disorder: investigation of placebo response in a pharmacological treatment study of post-traumatic stress disorder","volume":"38","author":"Hodgins","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2011.12.008","article-title":"Clinical relevance of comorbidity in anxiety disorders: a report from The Netherlands Study of Depression and Anxiety (NESDA)","volume":"137","author":"Hofmeijer-Sevink","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109418_bib109","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/wps.21010","article-title":"Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study","volume":"21","author":"H\u00f8jlund","year":"2022","journal-title":"World Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib110","article-title":"Neuropeptide and small transmitter coexistence: fundamental studies and relevance to mental illness","volume":"12","author":"H\u00f6kfelt","year":"2018","journal-title":"Front. Neural Circ."},{"key":"10.1016\/j.neuropharm.2023.109418_bib111","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamapsychiatry.2022.1717","article-title":"Balovaptan vs placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial","volume":"79","author":"Hollander","year":"2022","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib112","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.neubiorev.2008.03.006","article-title":"Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease","volume":"32","author":"Holmes","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib113","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.tips.2003.09.011","article-title":"Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders","volume":"24","author":"Holmes","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tips.2009.10.003","article-title":"Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine","volume":"31","author":"Holmes","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib115","article-title":"Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches","volume":"12","author":"Hoskins","year":"2021","journal-title":"Eur. J. Psychotraumatol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib116","article-title":"Pharmacological-assisted psychotherapy for post traumatic stress disorder: a systematic review and meta-analysis","volume":"12","author":"Hoskins","year":"2021","journal-title":"Eur. J. Psychotraumatol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib117","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbi.2017.01.021","article-title":"Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: case-controlled study","volume":"62","author":"Hou","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2023.109418_bib118","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12888-022-03867-6","article-title":"The efficacy and acceptability of exposure therapy for the treatment of post-traumatic stress disorder in children and adolescents: a systematic review and meta-analysis","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib119","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0269881120965915","article-title":"A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: a systematic review and meta-analysis","volume":"35","author":"Illingworth","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib120","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib121","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib122","article-title":"Randomized controlled experimental study of hydrocortisone and D-cycloserine effects on fear extinction in PTSD","volume":"1\u20138","author":"Inslicht","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib123","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/joim.13406","article-title":"Hypocretins (orexins): the ultimate translational neuropeptides","volume":"291","author":"Jacobson","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib124","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/da.22854","article-title":"Systematic review and meta-analysis: dose\u2013response curve of SSRIs and SNRIs in anxiety disorders","volume":"36","author":"Jakubovski","year":"2019","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib126","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1152\/physrev.00031.2017","article-title":"The oxytocin receptor: from intracellular signaling to behavior","volume":"98","author":"Jurek","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib127","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1126\/science.1214592","article-title":"Fear erasure in mice requires synergy between antidepressant drugs and extinction training","volume":"334","author":"Karpova","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109418_bib128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/bcpt.12037","article-title":"Chronic administration of infliximab (TNF-\u03b1 inhibitor) decreases depression and anxiety-like behaviour in rat model of chronic mild stress","volume":"112","author":"Karson","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib129","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-neuro-062111-150420","article-title":"Multiple functions of endocannabinoid signaling in the brain","volume":"35","author":"Katona","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41398-022-02094-7","article-title":"The role of the immune system in posttraumatic stress disorder","volume":"12","author":"Katrinli","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib131","article-title":"Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313","volume":"108","author":"Kaufmann","year":"2021","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib132","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/0269881116675781","article-title":"The role of psychedelics in palliative care reconsidered: a case for psilocybin","volume":"30","author":"Kelmendi","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib133","article-title":"The association of anxiety and stress-related disorders with C-reactive protein (CRP) within UK Biobank","volume":"19","author":"Kennedy","year":"2022","journal-title":"Brain Behav. Immun. Health"},{"key":"10.1016\/j.neuropharm.2023.109418_bib134","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib135","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.3390\/antiox9020107","article-title":"Inflammation in post-traumatic stress disorder (PTSD): a review of potential correlates of PTSD with a neurological perspective","volume":"9","author":"Kim","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.neuropharm.2023.109418_bib136","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/1570159X15666170913110426","article-title":"Neuroinflammation and the immune-kynurenine pathway in anxiety disorders","volume":"16","author":"Kim","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib137","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1176\/appi.focus.20200047","article-title":"Psychedelics as reemerging treatments for anxiety disorders: possibilities and challenges in a nascent field","volume":"19","author":"King","year":"2021","journal-title":"FOC"},{"key":"10.1016\/j.neuropharm.2023.109418_bib138","article-title":"Sustained effects of single doses of classical psychedelics in humans","author":"Knudsen","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib139","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neubiorev.2017.03.007","article-title":"Serotonin and neuroplasticity - links between molecular, functional and structural pathophysiology in depression","volume":"77","author":"Kraus","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib140","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the potential of psychedelics for the treatment of PTSD","volume":"23","author":"Krediet","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib141","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109418_bib142","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cell.2020.02.033","article-title":"A new rapid-acting antidepressant","volume":"181","author":"Krystal","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109418_bib143","article-title":"It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group","volume":"82","author":"Krystal","year":"2017","journal-title":"Biol. Psycjiatr. Stress: Mech. Gut. Brain"},{"key":"10.1016\/j.neuropharm.2023.109418_bib144","article-title":"Psychotherapy-supported MDMA treatment for PTSD","volume":"2","author":"Krystal","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2022.101010","article-title":"Sex hormone fluctuation and increased female risk for depression and anxiety disorders: from clinical evidence to molecular mechanisms","volume":"66","author":"Kundakovic","year":"2022","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib146","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/bs12080262","article-title":"Anxiety and depression: what do we know of neuropeptides?","volume":"12","author":"Kupcova","year":"2022","journal-title":"Behav. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib147","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00213-021-05861-4","article-title":"The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study","volume":"238","author":"Lago","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112631","article-title":"Ketamine's dose related multiple mechanisms of actions: dissociative anesthetic to rapid antidepressant","volume":"390","author":"Lavender","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib149","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1176\/appi.ajp.2016.16030353","article-title":"Using neuroscience to help understand fear and anxiety: a two-system framework","volume":"173","author":"LeDoux","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib150","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1038\/s41380-022-01498-7","article-title":"Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear","volume":"27","author":"Lee","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib151","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11920-021-01235-x","article-title":"Understanding the connection between the gut\u2013brain Axis and stress\/anxiety disorders","volume":"23","author":"Lee","year":"2021","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2023.109418_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.brat.2021.103924","article-title":"A randomized, double-blind, placebo-controlled trial of hydrocortisone augmentation of Prolonged Exposure for PTSD in U.S. combat veterans","volume":"144","author":"Lehrner","year":"2021","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.neuropharm.2023.109418_bib153","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/wps.20941","article-title":"The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses","volume":"21","author":"Leichsenring","year":"2022","journal-title":"World Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib154","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2016.08.067","article-title":"A cortical circuit for sexually dimorphic oxytocin-dependent anxiety behaviors","volume":"167","author":"Li","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109418_bib155","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/da.22546","article-title":"Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder","volume":"33","author":"Liebowitz","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib156","first-page":"675","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.neuropharm.2023.109418_bib157","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis","volume":"74","author":"Locher","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib158","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2011.00055","article-title":"Neurosteroids as neuromodulators in the treatment of anxiety disorders","volume":"2","author":"Longone","year":"2011","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib159","article-title":"Mechanisms of fear learning and extinction: synaptic plasticity\u2013fear memory connection","author":"Luchkina","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib160","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrn4036","article-title":"The endocannabinoid system in guarding against fear, anxiety and stress","volume":"16","author":"Lutz","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib161","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2023.109418_bib162","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12888-020-02793-9","article-title":"A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol","volume":"20","author":"Maier","year":"2020","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib163","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195521","article-title":"Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain","volume":"13","author":"Makunts","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109418_bib164","doi-asserted-by":"crossref","first-page":"229","DOI":"10.31887\/DCNS.2020.22.3\/rmaldonado","article-title":"The endocannabinoid system in modulating fear, anxiety, and stress","volume":"22","author":"Maldonado","year":"2020","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib165","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1134\/S1068162021030122","article-title":"Current approaches to the search of anxiolytic drugs","volume":"47","author":"Maltsev","year":"2021","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.neuropharm.2023.109418_bib166","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/02698811211069124","article-title":"A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults","volume":"36","author":"Maples-Keller","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib167","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbi.2021.12.025","article-title":"The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members","volume":"101","author":"Maples-Keller","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2023.109418_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamapsychiatry.2019.4833","article-title":"Multimodal categorical and dimensional approaches to understanding threat conditioning and its extinction in individuals with anxiety disorders","volume":"77","author":"Marin","year":"2020","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib169","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22com14647","article-title":"Lost in translation: the value of psychiatric clinical trials","volume":"83","author":"Markowitz","year":"2022","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib170","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1523\/JNEUROSCI.1647-20.2020","article-title":"Limbic neuropeptidergic modulators of emotion and their therapeutic potential for anxiety and post-traumatic stress disorder","volume":"41","author":"Marvar","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib171","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib172","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","article-title":"D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data","volume":"74","author":"Mataix-Cols","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib173","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1176\/appi.ajp.162.12.2379","article-title":"Open-label trial of riluzole in generalized anxiety disorder","volume":"162","author":"Mathew","year":"2005","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib174","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41380-018-0215-1","article-title":"Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice","volume":"25","author":"Mayo","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2019.07.034","article-title":"Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial","volume":"87","author":"Mayo","year":"2020","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib176","first-page":"262","article-title":"Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biological psychiatry","volume":"91","author":"Mayo","year":"2022","journal-title":"Novel Neuromodulators of Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib177","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbi.2020.07.037","article-title":"Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors","volume":"89","author":"Mazza","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2023.109418_bib178","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbi.2021.02.021","article-title":"Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up","volume":"94","author":"Mazza","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2023.109418_bib179","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"McClure-Begley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109418_bib180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jpsychires.2011.03.006","article-title":"Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness","volume":"45","author":"McLean","year":"2011","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.janxdis.2022.102607","article-title":"Exposure therapy for PTSD in military populations: a systematic review and meta-analysis of randomized clinical trials","volume":"90","author":"McLean","year":"2022","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.neuropharm.2023.109418_bib182","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.3390\/ijms22041863","article-title":"Cannabidiol as a potential treatment for anxiety and mood disorders: molecular targets and epigenetic insights from preclinical research","volume":"22","author":"Melas","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib183","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/npp.2017.227","article-title":"Neural underpinnings of cortisol effects on fear extinction","volume":"43","author":"Merz","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib184","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.psyneuen.2017.05.023","article-title":"Dexamethasone facilitates fear extinction and safety discrimination in PTSD: a placebo-controlled, double-blind study","volume":"83","author":"Michopoulos","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/npp.2016.146","article-title":"Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond","volume":"42","author":"Michopoulos","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib186","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221105128","article-title":"Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action","volume":"12","author":"Millan","year":"2022","journal-title":"Therapeut. Adv. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib187","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/npp.2015.316","article-title":"Multiple nicotinic acetylcholine receptor subtypes in the mouse amygdala regulate affective behaviors and response to social stress","volume":"41","author":"Mineur","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib188","article-title":"Neuroplasticity and environment: a pharmacotherapeutic approach toward preclinical and clinical understanding","volume":"19","author":"Mishra","year":"2021","journal-title":"Curr. Opin. Environ. Sci. Health"},{"key":"10.1016\/j.neuropharm.2023.109418_bib189","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib190","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib191","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0006-3223(99)00239-5","article-title":"Plasma neuropeptide-Y concentrations in humans exposed to military survival training","volume":"47","author":"Morgan","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib192","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2215-0366(21)00154-1","article-title":"The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action","volume":"8","author":"Murphy","year":"2021","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib193","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11920-017-0819-1","article-title":"Oxytocin and anxiety disorders: translational and therapeutic aspects","volume":"19","author":"Naja","year":"2017","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2023.109418_bib194","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fpsyt.2020.548505","article-title":"Glutamate systems in DSM-5 anxiety disorders: their role and a review of glutamate and GABA psychopharmacology","volume":"11","author":"Nasir","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib195","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib196","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biopsych.2015.06.004","article-title":"Oxytocin in general anxiety and social fear: a translational approach","volume":"79","author":"Neumann","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib197","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.863088","article-title":"Entactogens: how the name for a novel class of psychoactive agents originated","volume":"13","author":"Nichols","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib198","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jamapsychiatry.2021.2573","article-title":"Perturbations in gut microbiota composition in psychiatric disorders: a review and meta-analysis","volume":"78","author":"Nikolova","year":"2021","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib199","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.598119","article-title":"Nutrition as metabolic treatment for anxiety","volume":"12","author":"Norwitz","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib200","article-title":"The current status of psychedelics in psychiatry","author":"Nutt","year":"2020","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.565583","article-title":"Augmenting clinical interventions in psychiatric disorders: systematic review and update on nutrition","volume":"12","author":"Offor","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib202","doi-asserted-by":"crossref","first-page":"21m14336","DOI":"10.4088\/JCP.21m14336","article-title":"Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation, and generalized anxiety symptoms: a retrospective chart review","volume":"83","author":"Oliver","year":"2022","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib203","first-page":"91","article-title":"Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes","volume":"17","author":"Otto","year":"2010","journal-title":"Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib204","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuron.2014.10.007","article-title":"Improving and accelerating drug development for nervous system disorders","volume":"84","author":"Pankevich","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109418_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2022.100468","article-title":"Adjunct treatment with ketamine enhances the therapeutic effects of extinction learning after chronic unpredictable stress","volume":"19","author":"Paredes","year":"2022","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.neuropharm.2023.109418_bib206","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neubiorev.2016.12.033","article-title":"The endocannabinoid system as a target for novel anxiolytic drugs","volume":"76","author":"Patel","year":"2017","journal-title":"Neurosci. Biobehav. Rev. Transl. Neurosci. Mental Disorder.: Bridg. Gap Anim Model. Him. Condit."},{"key":"10.1016\/j.neuropharm.2023.109418_bib207","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/NDT.S242040","article-title":"The potential role of epigenetic drugs in the treatment of anxiety disorders","volume":"16","author":"Peedicayil","year":"2020","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2023.109418_bib208","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neubiorev.2020.04.023","article-title":"Exogenous effects of oxytocin in five psychiatric disorders: a systematic review, meta-analyses and a personalized approach through the lens of the social salience hypothesis","volume":"114","author":"Peled-Avron","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib209","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(21)00359-7","article-title":"Anxiety disorders","volume":"397","author":"Penninx","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2023.109418_bib210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0140-6736(21)00931-4","article-title":"Benzodiazepines for the long-term treatment of anxiety disorders? - authors' reply","volume":"398","author":"Penninx","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2023.109418_bib211","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/cells11111826","article-title":"Dysfunctional heteroreceptor complexes as novel targets for the treatment of major depressive and anxiety disorders","volume":"11","author":"P\u00e9rez de la Mora","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2023.109418_bib212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-01141-5","article-title":"Cholinergic modulation of disorder-relevant human defensive behaviour in generalised anxiety disorder","volume":"11","author":"Perkins","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib213","first-page":"1","article-title":"Inflammatory and oxidative stress markers in post-traumatic stress disorder: a systematic review and meta-analysis","author":"Peruzzolo","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib214","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41386-020-0738-4","article-title":"Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the fast-fail trial in mood and anxiety spectrum disorders (FAST-MAS)","volume":"45","author":"Pizzagalli","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jbtep.2015.01.002","article-title":"Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a motor vehicle accident. A randomized clinical trial - the \u201cTRAKT\u201d study","volume":"48","author":"Popiel","year":"2015","journal-title":"J. Behav. Ther. Exp. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib216","series-title":"Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments","first-page":"163","article-title":"The role of the glutamate system in posttraumatic stress disorder and glutamate-based treatments","author":"Popoli","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109418_bib217","volume":"2","author":"Pradhan","year":"2017","journal-title":"Asia pacif. J. Clin. Trials: Nervous Syst. Dis."},{"key":"10.1016\/j.neuropharm.2023.109418_bib218","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2023.109418_bib219","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","article-title":"Psilocybin induces time-dependent changes in global functional connectivity","volume":"88","author":"Preller","year":"2020","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib221","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/JCP.0000000000001591","article-title":"Panic disorder seeks more specific drugs for treatment: might the amygdala Be the best target?","volume":"42","author":"Quagliato","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib222","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13062","article-title":"A role for deficits in GABAergic neurosteroids and their metabolites with NMDA receptor antagonist activity in the pathophysiology of posttraumatic stress disorder","volume":"34","author":"Rasmusson","year":"2022","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib223","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamapsychiatry.2018.3412","article-title":"Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder","volume":"76","author":"Rauch","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib224","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jpsychires.2022.03.045","article-title":"Effects of propranolol on the modification of trauma memory reconsolidation in PTSD patients: a systematic review and meta-analysis","volume":"150","author":"Raut","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108195","article-title":"Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation","volume":"239","author":"Raut","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2023.109418_bib226","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1192\/bja.2020.82","article-title":"The immunology of stress and the impact of inflammation on the brain and behavior","volume":"27","author":"Ravi","year":"2021","journal-title":"BJPsych Adv."},{"key":"10.1016\/j.neuropharm.2023.109418_bib227","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jnc.15587","article-title":"The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)","volume":"162","author":"Reckweg","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109418_bib228","first-page":"99","article-title":"Neuropeptide Y: a stressful review. Neuropeptides","volume":"55","author":"Reichmann","year":"2016","journal-title":"Adv. NPY Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib229","first-page":"391","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.neuropharm.2023.109418_bib230","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/da.22790","article-title":"The association between anxiety, traumatic stress, and obsessive\u2013compulsive disorders and chronic inflammation: a systematic review and meta-analysis","volume":"35","author":"Renna","year":"2018","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib231","first-page":"214","article-title":"Translating across circuits and genetics toward progress in fear- and anxiety-related disorders","volume":"177","author":"Ressler","year":"2020","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.neuropharm.2023.109418_bib232","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41582-022-00635-8","article-title":"Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits","volume":"18","author":"Ressler","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib233","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","article-title":"Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib234","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1101\/lm.78204","article-title":"Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications","volume":"11","author":"Richardson","year":"2004","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuropharm.2023.109418_bib235","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41380-018-0272-5","article-title":"Animal models of PTSD: a challenge to be met","volume":"24","author":"Richter-Levin","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib236","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41398-020-00942-y","article-title":"Neuroinflammatory alterations in trait anxiety: modulatory effects of minocycline","volume":"10","author":"Rooney","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.janxdis.2019.102149","article-title":"Changes in dosing and dose timing of D-cycloserine explain its apparent declining efficacy for augmenting exposure therapy for anxiety-related disorders: an individual participant-data meta-analysis","volume":"68","author":"Rosenfield","year":"2019","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.neuropharm.2023.109418_bib238","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31887\/DCNS.2015.17.2\/proybyrne","article-title":"Treatment-refractory anxiety; definition, risk factors, and treatment challenges","volume":"17","author":"Roy-Byrne","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib239","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1037\/ccp0000452","article-title":"Integrating the hierarchical Taxonomy of psychopathology (HiTOP) into clinical practice","volume":"87","author":"Ruggero","year":"2019","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.759626","article-title":"Acute ketamine facilitates fear memory extinction in a rat model of PTSD along with restoring glutamatergic alterations and dendritic atrophy in the prefrontal cortex","volume":"13","author":"Sala","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib241","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-00937-9","article-title":"Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans","volume":"10","author":"Salvadore","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib242","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41583-021-00540-x","article-title":"The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders","volume":"23","author":"Sanacora","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib243","series-title":"Progress in Personalized Psychiatric Therapy with the Example of Using Intranasal Oxytocin in PTSD Treatment","author":"Szafoni","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109418_bib244","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"Santomauro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2023.109418_bib245","article-title":"Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review","author":"Santos","year":"2018","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib246","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0706743720979917","volume":"66","author":"Sarris","year":"2021","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib247","first-page":"1","article-title":"Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the World federation of societies of biological psychiatry (WFSBP) and Canadian network for mood and anxiety treatments (CANMAT) taskforce","author":"Sarris","year":"2022","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109418_bib249","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/npp.2015.210","article-title":"Dexamethasone treatment leads to enhanced fear extinction and dynamic Fkbp5 regulation in amygdala","volume":"41","author":"Sawamura","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ijnp\/pyx109","article-title":"A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder","volume":"21","author":"Sayed","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib251","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/17425255.2021.1991912","article-title":"The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics","volume":"17","author":"Scherf-Clavel","year":"2021","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib252","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00213-021-06027-y","article-title":"Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review","volume":"239","author":"Schimmel","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109418_bib253","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12646","article-title":"Sex differences in mechanisms of disease","volume":"19","author":"Shansky","year":"2020","journal-title":"Gene Brain Behav."},{"key":"10.1016\/j.neuropharm.2023.109418_bib254","doi-asserted-by":"crossref","first-page":"20l13406","DOI":"10.4088\/JCP.20l13406","article-title":"A proof-of-concept study of subanesthetic intravenous ketamine combined with prolonged exposure therapy among veterans with posttraumatic stress disorder","volume":"81","author":"Shiroma","year":"2020","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib255","article-title":"Ketamine effects on anxiety and fear-related behaviors: current literature evidence and new findings","volume":"100","author":"Silote","year":"2020","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib256","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpr.2020.101943","article-title":"The gut microbiota in anxiety and depression \u2013 a systematic review","volume":"83","author":"Simpson","year":"2021","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib257","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00213-018-5054-x","article-title":"Rodent models of impaired fear extinction","volume":"236","author":"Singewald","year":"2019","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2023.109418_bib258","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","article-title":"Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders","volume":"149","author":"Singewald","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2023.109418_bib259","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2023.109418_bib260","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","article-title":"MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis","volume":"62","author":"Smith","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib261","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6777","article-title":"Dose timing of D-cycloserine to augment exposure therapy for social anxiety disorder: a randomized clinical trial","volume":"3","author":"Smits","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuropharm.2023.109418_bib262","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.3390\/jcm11144039","article-title":"An updated review on the psychoactive, toxic and anticancer properties of Kava","volume":"11","author":"Soares","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib263","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jad.2021.08.108","article-title":"The 9-year clinical course of depressive and anxiety disorders: new NESDA findings","volume":"295","author":"Solis","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109418_bib264","doi-asserted-by":"crossref","first-page":"20m13233","DOI":"10.4088\/JCP.20m13233","article-title":"Randomized controlled trial of riluzole augmentation for posttraumatic stress disorder: efficacy of a glutamatergic modulator for antidepressant-resistant symptoms","volume":"81","author":"Spangler","year":"2020","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41398-020-01177-7","article-title":"Fear extinction learning and anandamide: an fMRI study in healthy humans","volume":"11","author":"Spohrs","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib266","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.1503\/jpn.220072-l","article-title":"Updated and rectified meta-analysis shows no effect of propranolol versus placebo on traumatic memory reconsolidation disruption","volume":"47","author":"Steenen","year":"2022","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib267","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.biopsych.2021.05.012","article-title":"Randomized, placebo-controlled trial of the angiotensin receptor antagonist losartan for posttraumatic stress disorder","volume":"90","author":"Stein","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib268","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm00187a001","article-title":"The benzodiazepine story","volume":"22","author":"Sternbach","year":"1979","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109418_bib269","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1017\/S0033291719001387","article-title":"Neural signatures of conditioning, extinction learning, and extinction recall in posttraumatic stress disorder: a meta-analysis of functional magnetic resonance imaging studies","volume":"50","author":"Suarez-Jimenez","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109418_bib270","author":"Summers"},{"key":"10.1016\/j.neuropharm.2023.109418_bib271","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S2215-0366(20)30462-4","article-title":"Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib272","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(21)00934-X","article-title":"Benzodiazepines for the long-term treatment of anxiety disorders?","volume":"398","author":"Tibrewal","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2023.109418_bib273","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00213-021-05787-x","article-title":"Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology","volume":"238","author":"Tricklebank","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib274","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15374","article-title":"Ketamine treatment for refractory anxiety: a systematic review","author":"Tully","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib275","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/jnr.24589","article-title":"Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis","volume":"98","author":"Tural","year":"2020","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib276","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/da.22664","article-title":"Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?","volume":"34","author":"Turna","year":"2017","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib277","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.euroneuro.2018.06.006","article-title":"New approaches in psychiatric drug development","volume":"28","author":"van der Doef","year":"2018","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109418_bib278","doi-asserted-by":"crossref","DOI":"10.2196\/26736","article-title":"The effectiveness of virtual reality exposure-based cognitive behavioral therapy for severe anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: meta-analysis","volume":"24","author":"van Loenen","year":"2022","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib279","article-title":"The missing piece? A case for microglia's prominent role in the therapeutic action of anesthetics, ketamine, and psychedelics","author":"VanderZwaag","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib280","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.727117","article-title":"Psychedelics and other psychoplastogens for treating mental illness","volume":"12","author":"Vargas","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib281","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.906639","article-title":"Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects","volume":"13","author":"Vizeli","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib282","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/a-1721-2914","article-title":"Classic psychedelic drugs: update on biological mechanisms","volume":"55","author":"Vollenweider","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib283","series-title":"Physiological and Cellular Targets of Neurotrophic Anxiolytic Phytochemicals in Food and Dietary Supplements","author":"Weeks","year":"2021"},{"key":"10.1016\/j.neuropharm.2023.109418_bib284","first-page":"1","article-title":"Abnormal dynamic functional connectivity during fear extinction learning in PTSD and anxiety disorders","author":"Wen","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib285","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/da.23065","article-title":"Historic psychedelic drug trials and the treatment of anxiety disorders","volume":"37","author":"Weston","year":"2020","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109418_bib286","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211056743","article-title":"Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders","volume":"11","author":"Whittaker","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109418_bib287","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.231","article-title":"Enhancing dopaminergic signaling and histone acetylation promotes long-term rescue of deficient fear extinction","volume":"6","author":"Whittle","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109418_bib288","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1042\/BST20130233","article-title":"HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand?","volume":"42","author":"Whittle","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2023.109418_bib289","article-title":"Pharmacotherapy for post traumatic stress disorder (PTSD)","author":"Williams","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib290","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biopsych.2019.12.013","article-title":"Cholinergic modulation of disorder-relevant neural circuits in generalized anxiety disorder","volume":"87","author":"Wise","year":"2020","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib291","article-title":"The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","volume":"173321","author":"Witkin","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109418_bib292","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109418_bib293","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.3390\/ijms21186546","article-title":"Neuroinflammation-associated alterations of the brain as potential neural biomarkers in anxiety disorders","volume":"21","author":"Won","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109418_bib294","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.biopsych.2021.12.019","article-title":"Orexin 1 receptor antagonism in the basolateral amygdala shifts the balance from pro- to antistress signaling and behavior","volume":"91","author":"Yaeger","year":"2022","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib295","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1038\/s41380-020-0755-z","article-title":"A DNA methylation clock associated with age-related illnesses and mortality is accelerated in men with combat PTSD","volume":"26","author":"Yang","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109418_bib296","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s00213-017-4684-8","article-title":"Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)","volume":"234","author":"Young","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109418_bib297","doi-asserted-by":"crossref","first-page":"958","DOI":"10.30773\/pi.2021.0209","article-title":"Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis","volume":"18","author":"Yu","year":"2021","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.neuropharm.2023.109418_bib298","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neubiorev.2020.03.015","article-title":"Therapeutic potential of glutathione-enhancers in stress-related psychopathologies","volume":"114","author":"Zalachoras","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109418_bib299","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106204","article-title":"Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis","volume":"179","author":"Zhang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2023.109418_bib300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2019.100196","article-title":"Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond","volume":"11","author":"Zorumski","year":"2019","journal-title":"Neurobiol. Stress"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:10:02Z","timestamp":1777389002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":300,"alternative-id":["S0028390823000084"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109418","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109418"}}